Hostname: page-component-cb9f654ff-lqqdg Total loading time: 0 Render date: 2025-08-07T07:28:35.956Z Has data issue: false hasContentIssue false
  • English
  • Français

Apolipoprotein E genotype modulates the effect of black tea drinking on blood lipids and blood coagulation factors: a pilot study

Published online by Cambridge University Press:  09 March 2007

Alexandre Loktionov ,
Sheila A. Bingham ,
Hester Vorster ,
Johann C. Jerling ,
Shirley A. Runswick  and
John H. Cummings
Alexandre Loktionov*
Affiliation:
Medical Research Council, Dunn Clinical Nutrition Centre, Hills Road, Cambridge CB2 2DH, UK
Sheila A. Bingham
Affiliation:
Medical Research Council, Dunn Clinical Nutrition Centre, Hills Road, Cambridge CB2 2DH, UK
Hester Vorster
Affiliation:
Department of Nutrition, Potchefstroom University for Christian Higher Education, Potchefstroom, South Africa
Johann C. Jerling
Affiliation:
Department of Nutrition, Potchefstroom University for Christian Higher Education, Potchefstroom, South Africa
Shirley A. Runswick
Affiliation:
Medical Research Council, Dunn Clinical Nutrition Centre, Hills Road, Cambridge CB2 2DH, UK
John H. Cummings
Affiliation:
Medical Research Council, Dunn Clinical Nutrition Centre, Hills Road, Cambridge CB2 2DH, UK
*
*Corresponding author:Dr A. Loktionov, fax +44 (0) 1223 413763, email Alex.Loktionov@mrc-dunn.cam.ac.uk
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Apolipoprotein E (ApoE) genotype was determined in sixty-five subjects who had taken part in a 4-week randomized crossover trial to compare the effect of six mugs of black tea per day v. placebo on blood lipids and blood coagulation factors. Four ApoE genotype variants (seven E2/E3, forty-five E3/E3, twelve E3/E4 and one E4/E4) were found. ApoE allele frequency was within the range typical for Caucasian populations (ApoE-E2 5·4 %; ApoE-E3 83·8 %; ApoE-E4 10·8 %). Individuals bearing at least one E4 allele had substantially higher levels of serum total cholesterol, LDL cholesterol and triacylglycerols. Mean plasminogen activator inhibitor (PAI-1) activity was higher in ApoE-E4 allele-bearing individuals (E3/E4 + E4/E4, 11·89 (SE 1·27) U/ml; E3/E3, 9·19 (SE 0·80) U/ml; E2/E3, 7·21 (SE 1·04) U/ml, P values of E4-group v. E3 and E2 being respectively 0·093 and 0·030). These unexpected findings imply that elevated PAI-1 activity may be a hitherto unrecognized additional factor involved in the increased cardiovascular disease risk associated with apoE-E4 allele. The interactions between tea drinking and genotype were also examined. In the E3/E3 homozygotes, HDL-cholesterol was significantly reduced in the tea period (mean placebo 1·54 mmol/l v. mean tea 1·50 mmol/l, P = 0·027). In the E2/E3 group, triacylglycerol concentration was significantly reduced (mean placebo 1·18 mmol/l v. mean tea 1·09 mmol/l, P = 0·039). Tea also caused a significant decrease of PAI-1 activity in the subjects with E2/E3 genotype (mean placebo 7·21 U/ml v. mean tea 5.88 U/ml, P = 0·007). In the other two genotype groups, there was no significant effect of tea. The results indicate that tea drinking has a beneficial effect on some cardiovascular disease risk-associated factors, especially in E2 allele-bearing individuals. Dietary intervention may be particularly effective in population groups with certain genetic characteristics.

Keywords

ApolipoproteinsCardiovascular diseaseGenotypeDietary interventionTea

Information

Type
Human and Clinical Nutrition
Information
British Journal of Nutrition , Volume 79 , Issue 2 , February 1998 , pp. 133 - 139
Copyright
Copyright © The Nutrition Society 1998

References

Bingham, SA, Vorster, H, Jerling, JC, Magee, E, Mulligan, A, Runswick, SA & Cummings, JH (1997) Effect of black tea drinking on blood lipids, blood pressure and aspects of bowel habit. British Journal of Nutrition 78, 41–55.CrossRefGoogle ScholarPubMed
Bredie, SJH, Vogelaar, JM, Demacker, PNM & Stalenhoef, AFH (1996) Apolipoprotein E polymorphism influences lipid phe-notypic expression, but not the low density lipoprotein subfraction distribution in familial combined hyperlipidemia. Atherosclerosis 126, 313–324.CrossRefGoogle Scholar
Bu, GJ, Maksymovitch, EA, Nerbonne, JM & Schwartz, AL (1994) Expression and function of low-density lipoprotein receptor-related protein (LRP) in mammalian central neurons. Journal of Biological Chemistry 269, 18521–18528.CrossRefGoogle ScholarPubMed
Castelli, WP (1996) Lipids, risk factors and ischaemic heart disease. Atherosclerosis 124, Suppl., S1-S9.CrossRefGoogle Scholar
Clauss, A (1957) Gerinnungsphysiologissche Schellmetode zur Bestimmung des Fibrinogens (A quick fibrinogen determination method based on clotting physiology). Acta Haematologica 17, 237–246.CrossRefGoogle Scholar
Dammerman, M & Breslow, JL (1995) Genetic basis of lipoprotein disorders. Circulation 91, 505–512.CrossRefGoogle ScholarPubMed
Davignon, J, Cregg, RE & Sing, CF (1988) Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 9, 405–411.Google Scholar
Department of Health (1994) Nutritional Aspects of Cardiovascular Disease. Report on Health and Social Subjects no. 46. London: H.M. Stationery Office.Google Scholar
Hamsten, A, De Faire, U, Walldius, G, Dahlen, G, Szamosi, A, Landou, C, Blombäck, M & Wiman, B (1987) Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet ii, 3–8.CrossRefGoogle Scholar
Hixson, JE & Vernier, DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. Journal of Lipid Research 31, 545–548.CrossRefGoogle Scholar
Jansen, JWCM & Reinders, JH (1992) Fibrinolysis: system and processes. Coronary Artery Disease 3, 425–434.CrossRefGoogle Scholar
Juhan-Vague, I & Alessi, MC (1997) PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thrombosis and Haemostasis 78, 656–660.Google ScholarPubMed
Kamboh, MI, Aston, CE & Hamman, RF (1995) The relationship of APOE polymorphism and cholesterol levels in normoglycemic and diabetic subjects in a biethnic population from the San Luis Valley, Colorado. Atherosclerosis 112, 145–159.CrossRefGoogle Scholar
Kannel, WB, Wolf, PA, Castelli, WP & D'Agostino, RB (1987) Fibrinogen and risk of cardiovascular disease. The Framingham study. Journal of the American Medical Association 258, 1183–1186.CrossRefGoogle ScholarPubMed
Kontula, K, Aalto-Setälä, K, Kuusi, T, Hämäläinen, L & Syvänen, A-C (1990) Apolipoprotein E polymorphism determined by restriction enzyme analysis of DNA amplified by polymerase chain reaction: convenient alternative to phenotyping by isoelectric focusing. Clinical Chemistry 36, 2087–2092.CrossRefGoogle ScholarPubMed
Mahley, RW (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240, 622–630.CrossRefGoogle ScholarPubMed
Manttari, M, Koskinen, P, Enholm, C, Huttunen, JK & Manninen, V (1991) Apolipoprotein E polymorphism influences the serum cholesterol response to dietary intervention. Metabolism 40, 217–221.CrossRefGoogle ScholarPubMed
Marshall, JA, Kamboh, MI, Bessesen, DH, Hoag, S, Hamman, RF & Ferrell, RE (1996). Associations between dietary factors and serum lipids by apolipoprotein E polymorphism. American Journal of Clinical Nutrition 63, 87–95.CrossRefGoogle ScholarPubMed
Nakata, Y, Katsaya, T, Rakugi, H, Takami, S, Ohishi, H, Kamino, K, Higaki, J, Tabuchi, Y, Kimahara, Y, Miki, T & Ogihara, T (1996) Polymorphism of the apolipoprotein-E and angiotensin-converting enzyme genes in Japanese subjects with silent myocardial ischemia. Hypertension 27, 1205–1209.CrossRefGoogle ScholarPubMed
Nilsson, TK, Sundell, IB, Hellsten, G & Hallmans, G (1990) Reduced plasminogen activator inhibitor activity in high consumers of fruits, vegetables and root vegetables. Journal of Internal Medicine 227, 267–271.CrossRefGoogle ScholarPubMed
Olofsson, BO, Dahlen, G & Nilsson, TK (1989) Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographi-cally verified coronary artery disease. European Heart Journal 10, 77–82.CrossRefGoogle ScholarPubMed
Paik, Y-K, Chang, DJ, Reardon, CA, Davies, GE, Mahley, RW & Taylor, JM (1985). Nucleotide sequence and structure of the human apolipoprotein E gene. Proceedings of the National Academy of Sciences USA 82, 3445–3449.CrossRefGoogle ScholarPubMed
Paramo, JA, Colucci, M, Collen, D & van de, Werf F (1985) Plasminogen activator inhibitor in the blood of patients with coronary heart disease. Lancet 291, 573–574.Google Scholar
Patsch, JR (1993) Is hypertriglyceridemia atherogenic? Atherosclerosis Reviews 25, 331–339.Google Scholar
Rebeck, GW, Harr, SD, Strickland, DK & Hyman, BT (1995) Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the Alpha(2)-macroglobulin receptor low-density-lipoprotein receptor protein. Annals of Neurology 37, 211–217.CrossRefGoogle Scholar
Routi, T, Rönnemaa, T, Salo, P, Seppänen, R, Marniemi, J, Viikari, J, Enholm, C & Simell, O (1996) Effects of prospective, randomized cholesterol-lowering dietary intervention and apolipoprotein E phenotype on serum lipoprotein(a) concentrations of infants aged 7–24 mo. American Journal of Clinical Nutrition 63, 386–391.CrossRefGoogle ScholarPubMed
Schächter, F, Faure-Delanef, L, Guénot, F, Rouger, H, Froguel, P, Lesueur-Ginot, L & Cohen, D (1994) Genetic associations with human longevity at the APOE and ACE loci. Nature Genetics 6, 29–32.CrossRefGoogle ScholarPubMed
Scheer, WD, Boudreau, DA, Malcolm, GT & Middaugh, JP (1995) Apolipoprotein E and atherosclerosis in Alaska Natives. Atherosclerosis 114, 197–202.CrossRefGoogle ScholarPubMed
Vorster, H, Jerling, J, Oosthuizen, W, Cummings, J, Bingham, S, Magee, L, Mulligan, A & Runswick, S (1996) Tea drinking and haemostasis: a randomised, placebo controlled, cross over study in free living subjects. Haemostasis 26, 58–64.Google ScholarPubMed
Weisgraber, KH & Mahley, RW (1996) Human apolipoprotein E: the Alzheimer's disease connection. FASEB Journal 10, 1485–1494.CrossRefGoogle ScholarPubMed
Wenham, PR, Price, WH & Blundell, G (1991) Apolipoprotein E genotyping by one-stage PCR. Lancet 337, 1158–1159.CrossRefGoogle ScholarPubMed
Wilson, PF, Myers, RH, Larson, MG, Ordovas, JM, Wolf, PA & Schaefer, EJ (1994) Apolipoprotein E alleles, dyslipidemia and coronary heart disease. The Framingham Offspring Study. Journal of the American Medical Association 272, 1666–1671.CrossRefGoogle ScholarPubMed
Wilson, PWF, Schaeffer, EJ, Larson, MG & Ordovas, JM (1996) Apolipoprotein-E alleles and risk of coronary disease – a meta-analysis. Arteriosclerosis, Thrombosis and Vascular Biology 16, 1250–1255.CrossRefGoogle ScholarPubMed
Xu, CF, Boerwinkle, E, Tikkanen, MJ, Huttunen, JK & Manninen, V (1990) Genetic variation at the apolipoprotein loci contribute to response of plasma lipids to dietary change. Genetic Epidemiology 7, 261–275.CrossRefGoogle ScholarPubMed